Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: May 22, 2015
Reporting Period: Specific event date of May 22, 2015
MediciNova, Inc. filed this report to disclose the entry into a new material definitive agreement regarding an at-the-market equity offering program and the termination of a prior agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate actions regarding equity financing.
Material Changes
- New Sales Agreement: Entered into an At-the-Market Issuance Sales Agreement with MLV & Co. LLC on May 22, 2015.
- Offering Capacity: The Company may issue and sell shares of common stock with an aggregate offering price of up to $30 million.
- Termination of Prior Agreement: Terminated the existing equity distribution agreement dated October 16, 2013, with Macquarie Capital (USA) Inc. (MCUSA).
- Commission Structure: MLV & Co. LLC will receive a commission of up to 4% of the gross proceeds from each sale.
Guidance, Outlook, and Risks
Management Commentary: The Company is not obligated to make any sales under the new agreement and may terminate the sales agreement at any time upon written notice. Sales will be made based on the Company's instructions regarding price, time, or size limits.
Risks and Contingencies:
- Registration Statement Dependency: The issuance and sale of shares are subject to the continued effectiveness of the Company's shelf registration statement on Form S-3 (File No. 333-185022). The Company makes no assurance as to its continued effectiveness.
- Market Conditions: Sales are subject to normal trading and sales practices and market conditions.
Investor Verification Checklist
- Verify the current status and effectiveness of the Company's Form S-3 shelf registration statement (File No. 333-185022).
- Review the full text of the At-the-Market Issuance Sales Agreement (Exhibit 10.1) for specific terms and conditions.
- Monitor future filings for actual share issuances and proceeds generated under the new $30 million program.
- Confirm the impact of the 4% commission on net proceeds relative to the Company's cash needs.